BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2027-01
167 industry Phase 2/3 trial readout(s) and 3 FDA decision event(s). Active trials only; estimated dates often slip.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-01-01 (quarter) | PDUFA date (company-disclosed) | pending | Biohaven Ltd. BHVN | PDUFA first quarter of 2027 - Biohaven Ltd. | |
| 2027-01-01 (quarter) | PDUFA date (company-disclosed) | pending | CorMedix Inc. CRMD | PDUFA Q1 2027 - CorMedix Inc. | |
| 2027-01-21 | PDUFA date (company-disclosed) | pending | Dyne Therapeutics, Inc. DYN | rostudirsen | PDUFA January 21, 2027 - Dyne Therapeutics, Inc. (rostudirsen) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P2 | Imvax | NCT04485949 A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | Glioblastoma | active not recruiting | 99 |
| 2027-01 est. | P1/P2 | BicycleTx Limited | NCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negative | active not recruiting | 329 |
| 2027-01 est. | P1/P2 | Eledon Pharmaceuticals ELDN | NCT05027906 Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | Prevention of Rejection in Kidney Transplant | recruiting | 48 |
| 2027-01 est. | P2 | Mirum Pharmaceuticals, Inc. MIRM | NCT05050136 A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Primary Biliary Cholangitis; PBC | active not recruiting | 333 |
| 2027-01 est. | P2 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT05171894 A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT | Port-wine Birthmarks; Port-Wine Stain; Nevus Flammeus | recruiting | 84 |
| 2027-01 est. | P3 | Vantive Health LLC | NCT05399537 Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | Regional Citrate Anticoagulation (RCA); Continuous Renal Replacement Therapy (CRRT); Acute Kidney In | recruiting | 40 |
| 2027-01 est. | P1/P2 | Vaderis Therapeutics AG | NCT05406362 Assess Safety and Efficacy of VAD044 in HHT Patients | Hereditary Hemorrhagic Telangiectasia (HHT) | active not recruiting | 75 |
| 2027-01 est. | P2 | Edgewise Therapeutics, Inc. EWTX | NCT05540860 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Duchenne Muscular Dystrophy | active not recruiting | 76 |
| 2027-01 est. | P3 | Biocad | NCT05751928 A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | Melanoma Stage III; Melanoma (Skin) | active not recruiting | 411 |
| 2027-01 est. | P2 | QBiotics Group Limited | NCT05755113 A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | Soft Tissue Sarcoma | recruiting | 40 |
| 2027-01 est. | P3 | EMS | NCT05824065 Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss | Female Pattern Baldness | not yet recruiting | 504 |
| 2027-01 est. | P1/P2 | LigaChem Biosciences, Inc. | NCT05941507 A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 300 |
| 2027-01 est. | P1/P2 | Skyline Therapeutics (US) Inc. | NCT05986864 Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | recruiting | 68 |
| 2027-01 est. | P2 | Gilead Sciences GILD | NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 176 |
| 2027-01 est. | P2 | Dr. F. Köhler Chemie GmbH | NCT06032195 Study of Organ Perfusion in Heart Transplantation in Children | Heart Transplantation | recruiting | 15 |
| 2027-01 est. | P2/P3 | AbbVie ABBV | NCT06109272 A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as a | Hepatocellular Carcinoma | active not recruiting | 89 |
| 2027-01 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06131450 A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic Malignancies | Gynecological Malignancies | recruiting | 158 |
| 2027-01 est. | P2 | OncoVerity, Inc. | NCT06384261 A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Leukemia, Myeloid, Acute | active not recruiting | 140 |
| 2027-01 est. | P1/P2 | Jacobio Pharmaceuticals Co., Ltd. | NCT06386146 JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Solid Tumors | recruiting | 144 |
| 2027-01 est. | P2 | Larimar Therapeutics, Inc. LRMR | NCT06447025 An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Friedreich Ataxia | recruiting | 85 |
| 2027-01 est. | P3 | Lexicon Pharmaceuticals LXRX | NCT06481891 A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Cardiomyopathy, Hypertrophic; Non-obstructive Hypertrophic Cardiomyopathy | active not recruiting | 500 |
| 2027-01 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06561607 A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | Breast Cancer | active not recruiting | 542 |
| 2027-01 est. | P3 | Akeso | NCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Head and Neck Squamous Cell Carcinoma | recruiting | 510 |
| 2027-01 est. | P3 | Ultragenyx Pharmaceutical Inc RARE | NCT06636071 Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | Osteogenesis Imperfecta | active not recruiting | 6 |
| 2027-01 est. | P2 | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | NCT06672978 A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acut | Acute Pyelonephritis; Complicated Urinary Tract Infection | active not recruiting | 66 |
| 2027-01 est. | P3 | AbbVie ABBV | NCT06701331 Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe | Atopic Dermatitis | active not recruiting | 99 |
| 2027-01 est. | P2 | Evopoint Biosciences Inc. | NCT06702605 To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma | Relapsed/Refractory Peripheral T Cell Lymphoma | not yet recruiting | 50 |
| 2027-01 est. | P1/P2 | AION Healthspan, Inc. | NCT06721143 A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered | Chronic Kidney Disease Stage 3 | recruiting | 36 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01 est. | P2 | Hope Biosciences Research Foundation | NCT06800404 "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" | Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis | active not recruiting | 10 |
| 2027-01 est. | P1/P2 | Marengo Therapeutics, Inc. | NCT06827613 A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govit | Triple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancer | recruiting | 50 |
| 2027-01 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06860971 A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma | Thyroid Cancer | recruiting | 144 |
| 2027-01 est. | P3 | Resilience | NCT06867705 Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only | Cancer | recruiting | 1458 |
| 2027-01 est. | P2/P3 | QED Therapeutics, a BridgeBio company | NCT06873035 An Interventional Study of Infigratinib in Children With Hypochondroplasia | Hypochondroplasia | enrolling by invitation | 24 |
| 2027-01 est. | P1/P2 | iOnctura | NCT06879717 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | Non-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLC | active not recruiting | 45 |
| 2027-01 est. | P2 | Zhejiang Teruisi Pharmaceutical Inc. | NCT06886139 A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. | CD20-positive Diffuse Large B-Cell Lymphoma | not yet recruiting | 139 |
| 2027-01 est. | P1/P2 | TenNor Therapeutics Inc. | NCT06889701 A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants | Periprosthetic Joint Infection (PJI) | recruiting | 33 |
| 2027-01 est. | P3 | Xenon Pharmaceuticals Inc. XENE | NCT06922110 An Open-Label Study of Azetukalner in Major Depressive Disorder | Major Depressive Disorder | active not recruiting | 460 |
| 2027-01 est. | P2 | BioMendics, LLC | NCT07027345 A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex | recruiting | 40 |
| 2027-01 est. | P2 | Greg Bew | NCT07032649 Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option | HSV | not yet recruiting | 100 |
| 2027-01 est. | P1/P2 | EyeD Pharma | NCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery | Glaucoma; Ocular Hypertension | recruiting | 42 |
| 2027-01 est. | P2 | Shanghai Henlius Biotech | NCT07038382 A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in P | Membranous Nephropathy; Lupus Nephritis (LN) | recruiting | 24 |
| 2027-01 est. | P3 | Telix Pharmaceuticals (Innovations) Pty Limited TLX | NCT07052214 PSMA PET Combined With MRI for the Detection of PCa | PCA; Prostate Cancer; Prostatic Neoplasm; PSMA PET; Diagnostic Imaging; Elevated PSA; Positron Emiss | active not recruiting | 338 |
| 2027-01 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT07062978 A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | Postmenopausal Women With Osteoporosis at High Risk of Fracture | recruiting | 278 |
| 2027-01 est. | P2 | Biocad | NCT07080034 Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis | Ulcerative Colitis (UC) | recruiting | 198 |
| 2027-01 est. | P3 | Sun Pharmaceutical Industries, Inc. | NCT07144345 Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | Actinic Keratosis | recruiting | 160 |
| 2027-01 est. | P3 | Sun Pharmaceutical Industries, Inc. | NCT07144852 Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | Actinic Keratosis | recruiting | 260 |
| 2027-01 est. | P3 | Shanghai Huilun Pharmaceutical Co., Ltd. | NCT07146386 A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia | Benign Prostatic Hyperplasia; Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | not yet recruiting | 728 |
| 2027-01 est. | P1/P2 | Alesta Therapeutics | NCT07179640 A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Su | Hypophosphatasia (HPP) | recruiting | 120 |
| 2027-01 est. | P2 | Hanmi Pharmaceutical Company Limited HAFC | NCT07205900 Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus | Obese; Obesity | active not recruiting | 267 |
| 2027-01 est. | P1/P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07208773 A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Advanced Solid Tumors; Non Small Cell Lung Cancer; Small Cell Lung Cancer | recruiting | 260 |
| 2027-01 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT07298772 A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | Advanced Solid Tumor | recruiting | 198 |
| 2027-01 est. | P2 | Newleos Therapeutics, Inc. | NCT07323784 A Study of NTX-1472 in Social Anxiety Disorder | Social Anxiety Disorder (SAD) | recruiting | 100 |
| 2027-01 est. | P1/P2 | Inflammasome Therapeutics | NCT07396818 Kamlanoflast In Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis); ALS; Neuro-Degenerative Disease; Neuro-Degenerative Diseases; M | not yet recruiting | 40 |
| 2027-01 est. | P2 | Synendos Therapeutics AG | NCT07478744 A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder | Generalized Anxiety Disorder | recruiting | 24 |
| 2027-01 est. | P2 | Aribio Lab Co., Ltd. | NCT07481604 Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above | Herpes Zoster | active not recruiting | 135 |
| 2027-01 est. | P3 | Praxis Precision Medicines PRAX | NCT07505004 Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | Focal Epilepsy | active not recruiting | 300 |
| 2027-01 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07505836 Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | Epidemic Meningitis; Meningococcal Vaccines | recruiting | 1040 |
| 2027-01 est. | P3 | Reistone Biopharma Company Limited | NCT07543224 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients W | Plaque Psoriasis Subjects | not yet recruiting | 600 |
| 2027-01 est. | P2 | Lakewood-Amedex Inc LABT | NCT07565506 Phase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU | Diabetic Foot Ulcers (DFUs) | recruiting | 24 |
| 2027-01 est. | P2/P3 | Hyundai Bioscience Co., Ltd. | NCT07576868 A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) | Dengue | recruiting | 210 |
| 2027-01 est. | P2 | Actio Biosciences, Inc. | NCT07600736 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-relate | KCNT1-Related Epilepsy | recruiting | 61 |
| 2027-01 est. | P3 | A. Menarini International Licensing S.A. | NCT07614958 Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial | Mixed Dyslipidemia; Hypercholesterolaemia | recruiting | 426 |
| 2027-01 est. | P1/P2 | Prolium Bioscience, Inc | NCT07641634 A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | Healthy Volunteers; Systemic Sclerosis (SSc); Scleroderma, Systemic; Scleroderma | recruiting | 44 |
| 2027-01 est. | P2 | Sensory Cloud, Inc. | NCT07690059 A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough | Refractory Chronic Cough and Unexplained Chronic Cough | recruiting | 60 |
| 2027-01 est. | P2 | Caravel Oculus Pty Ltd | NCT07694375 A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery | Corneal Endothelial Cell Loss; Corneal Endothelial Damage Following the Hard Nuclear Cataract Surger | recruiting | 200 |
| 2027-01 est. | P3 | Colgate Palmolive CL | NCT07842991 Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems | Plaque; Dental Plaque; Gingivitis | recruiting | 120 |
| 2027-01 est. | P3 | Adneuris Therapeutics, Inc. | NCT07845071 An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin | Pain | recruiting | 160 |
| 2027-01 est. | P2 | Aperta Biosciences, LLC | NCT07904767 A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis | Blepharitis | not yet recruiting | 15 |
| 2027-01 est. | P2 | Cristcot LLC | NCT07909291 A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 2 Study to Evaluate the Safety and Efficacy of Two Dosage Regimens of a Novel Hydrocortisone Ace | Hemorrhoidal Disease | not yet recruiting | 78 |
| 2027-01-01 est. | P2 | SIGA Technologies SIGA | NCT04957485 Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS | Smallpox | active not recruiting | 100 |
| 2027-01-01 est. | P2 | Biotheus Inc. | NCT05879055 A Study of PM8002 in Combination With Chemotherapy in Patients With NEN | Neuroendocrine Neoplasm | active not recruiting | 31 |
| 2027-01-01 est. | P2 | Tasly Biopharmaceuticals Co., Ltd. | NCT06838546 A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer | Advanced Colorectal Cancer | not yet recruiting | 80 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-01-03 est. | P2 | Shenzhen Kangzhe Biotechnology Co., Ltd. | NCT07402369 Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia | Uterine Fibroids With Menorrhagia | recruiting | 120 |
| 2027-01-04 est. | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06641089 Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Arthritis, Psoriatic | active not recruiting | 600 |
| 2027-01-04 est. | P3 | AstraZeneca AZN | NCT07000136 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | Heterozygous Familial Hypercholesterolaemia | active not recruiting | 473 |
| 2027-01-05 est. | P1/P2 | Hangzhou Sciwind Biosciences Co., Ltd. | NCT07243171 A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overwe | Overweight and/or Obesity; Weight Management | recruiting | 126 |
| 2027-01-05 est. | P3 | Shanghai Mabgeek Biotech.Co.Ltd | NCT07540442 A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | Dermatitis, Atopic | not yet recruiting | 180 |
| 2027-01-06 est. | P3 | AstraZeneca AZN | NCT05925803 Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | Systemic Sclerosis; Scleroderma | active not recruiting | 314 |
| 2027-01-06 est. | P1/P2 | Amgen AMGN | NCT06401044 A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | Thyroid Eye Disease | active not recruiting | 94 |
| 2027-01-06 est. | P1/P2 | Bristol-Myers Squibb BMY | NCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | Anemia, Sickle Cell; Healthy Volunteers | recruiting | 224 |
| 2027-01-06 est. | P1/P2 | Incyte Corporation INCY | NCT06843408 A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Chronic Graft-versus-host-disease | active not recruiting | 32 |
| 2027-01-06 est. | P3 | Norgine | NCT07218523 A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy | Bowel Cleansing Prior to Clinical Procedures | recruiting | 212 |
| 2027-01-07 est. | P3 | Sanofi SNY | NCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | Sickle Cell Disease | recruiting | 100 |
| 2027-01-08 est. | P3 | AstraZeneca AZN | NCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III | Non-Small Cell Lung Cancer | active not recruiting | 1051 |
| 2027-01-08 est. | P3 | Ocular Therapeutix, Inc. OCUL | NCT06495918 Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | active not recruiting | 825 |
| 2027-01-08 est. | P2 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | NCT06981091 A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Pati | Non-Cystic Fibrosis Bronchiectasis | active not recruiting | 234 |
| 2027-01-09 est. | P3 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | NCT07673029 A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | HER2-positive Breast Cancer | recruiting | 228 |
| 2027-01-10 est. | P3 | Celgene | NCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or | Relapsed or Refractory Multiple Myeloma | recruiting | 810 |
| 2027-01-11 est. | P1/P2 | LaNova Medicines Limited | NCT05615974 A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | Malignant Tumors | recruiting | 139 |
| 2027-01-11 est. | P3 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | NCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or | Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metasta | recruiting | 486 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EG | Metastatic Non-small Cell Lung Cancer | active not recruiting | 768 |
| 2027-01-11 est. | P2/P3 | EyeBiotech Ltd. | NCT06957080 A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | active not recruiting | 1054 |
| 2027-01-11 est. | P3 | AstraZeneca AZN | NCT07000123 A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Cardiovascular Disease | active not recruiting | 3103 |
| 2027-01-12 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung | Carcinoma, Non-Small-Cell Lung | active not recruiting | 614 |
| 2027-01-12 est. | P2 | GlaxoSmithKline | NCT07092865 A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following R | Respiratory Syncytial Virus Infections | active not recruiting | 168 |
| 2027-01-13 est. | P3 | iVascular S.L.U. | NCT05952206 Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy | Coronary Artery Disease | active not recruiting | 2312 |
| 2027-01-13 est. | P1/P2 | Avirmax Biopharma Inc | NCT06550011 Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With N | Neovascular (Wet) AMD | active not recruiting | 18 |
| 2027-01-13 est. | P3 | AstraZeneca AZN | NCT06706817 A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab | Chronic Rhinosinusitis With Nasal Polyps | active not recruiting | 181 |
| 2027-01-13 est. | P3 | Akeso | NCT06951503 AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Colorectal Adenocarcinoma | recruiting | 560 |
| 2027-01-14 est. | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT07261644 A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | Ankylosing Spondylitis | recruiting | 500 |
| 2027-01-14 est. | P2 | Novo Nordisk A/S NVO | NCT07395687 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity | Overweight; Obesity | recruiting | 333 |
| 2027-01-15 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04199689 Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | Papillomavirus Infections | active not recruiting | 6033 |
| 2027-01-15 est. | P3 | Bioverativ, a Sanofi company | NCT04644575 Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | Hemophilia A | active not recruiting | 261 |
| 2027-01-15 est. | P3 | Regeneron Pharmaceuticals REGN | NCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has | Melanoma | active not recruiting | 1564 |
| 2027-01-15 est. | P2/P3 | IDEAYA Biosciences IDYA | NCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | active not recruiting | 420 |
| 2027-01-15 est. | P2 | XBiotech, Inc. XBIT | NCT06590090 Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | Rheumatoid Arthritis | not yet recruiting | 108 |
| 2027-01-15 est. | P2 | Biostar Pharma, Inc. | NCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | 120 |
| 2027-01-15 est. | P2 | Huabo Biopharm Co., Ltd. | NCT07376629 A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | enrolling by invitation | 60 |
| 2027-01-16 est. | P1/P2 | Corbus Pharmaceuticals Inc. CRBP | NCT06265727 A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Solid Tumor, Adult | recruiting | 348 |
| 2027-01-16 est. | P3 | Novartis Pharmaceuticals NVS | NCT07102628 Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Acute Coronary Syndrome | active not recruiting | 305 |
| 2027-01-18 est. | P3 | Pfizer PFE | NCT05035212 Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | Lower Respiratory Tract Illness | active not recruiting | 38861 |
| 2027-01-18 est. | P3 | Takeda TAK | NCT05319353 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in C | Cytomegalovirus (CMV) | recruiting | 80 |
| 2027-01-18 est. | P2 | AstraZeneca AZN | NCT05374603 Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Lung Cancer | active not recruiting | 47 |
| 2027-01-18 est. | P1/P2 | Centre for Neuro Skills | NCT05786729 Aerobic Exercise After Traumatic Brain Injury | Traumatic Brain Injury | enrolling by invitation | 190 |
| 2027-01-18 est. | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT06686654 Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Yea | Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization | active not recruiting | 1530 |
| 2027-01-19 est. | P3 | Hoffmann-La Roche | NCT05170204 A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung C | Non-Small Cell Lung Cancer | active not recruiting | 68 |
| 2027-01-19 est. | P1/P2 | Sanofi SNY | NCT05584670 A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | recruiting | 542 |
| 2027-01-20 est. | P1/P2 | Creative Medical Technology Holdings Inc CELZ | NCT06053242 Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | Chronic Low-back Pain; Degenerative Disc Disease | active not recruiting | 45 |
| 2027-01-20 est. | P2/P3 | Turn Therapeutics TTRX | NCT07355075 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermati | Eczema Atopic Dermatitis; Eczema; Atopic Dermatitis | recruiting | 190 |
| 2027-01-21 est. | P3 | TG Therapeutics, Inc. TGTX | NCT05877963 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Relapsing Multiple Sclerosis | recruiting | 800 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Obesity | active not recruiting | 3853 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | active not recruiting | 1105 |
| 2027-01-21 est. | P2 | Laboratoires Thea | NCT07169695 A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis | Moderate to Severe Vernal Keratoconjunctivitis | recruiting | 120 |
| 2027-01-22 est. | P3 | Lupin Ltd. | NCT07097701 An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR | Myotonia | recruiting | 24 |
| 2027-01-23 est. | P1/P2 | Egle Therapeutics | NCT06622486 First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Solid Tumor, Adult | recruiting | 50 |
| 2027-01-24 est. | P2 | Chengdu Syncor Pharmaceutical Co., Ltd. | NCT07483671 Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients | Bacterial Vaginosis | not yet recruiting | 80 |
| 2027-01-25 est. | P1/P2 | Novartis Pharmaceuticals NVS | NCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lung | active not recruiting | 344 |
| 2027-01-25 est. | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT06696443 Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathic Pain | active not recruiting | 455 |
| 2027-01-25 est. | P3 | Novo Nordisk A/S NVO | NCT07076199 A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Ins | Diabetes Mellitus, Type 1 | active not recruiting | 877 |
| 2027-01-25 est. | P3 | Pfizer PFE | NCT07653100 A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF | Respiratory Syncytial Virus (RSV) | recruiting | 540 |
| 2027-01-26 est. | P3 | GlaxoSmithKline | NCT05757102 A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Asthma | active not recruiting | 138 |
| 2027-01-28 est. | P3 | Novartis Pharmaceuticals NVS | NCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatm | Breast Cancer | active not recruiting | 210 |
| 2027-01-28 est. | P3 | ModernaTX, Inc. | NCT07496450 A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Influenza | active not recruiting | 4050 |
| 2027-01-29 est. | P1/P2 | IDEAYA Biosciences IDYA | NCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumors | recruiting | 336 |
| 2027-01-29 est. | P2 | Novartis Pharmaceuticals NVS | NCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women Wit | Breast Neoplasms | active not recruiting | 69 |
| 2027-01-29 est. | P3 | Novartis Pharmaceuticals NVS | NCT04817618 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | C3G | recruiting | 98 |
| 2027-01-29 est. | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | active not recruiting | 412 |
| 2027-01-29 est. | P3 | Novo Nordisk A/S NVO | NCT06118281 ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Cardiovascular Risk; Acute Myocardial Infarction (AMI) | active not recruiting | 10000 |
| 2027-01-29 est. | P1/P2 | AstraZeneca AZN | NCT06151964 A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | Overweight and Obesity | active not recruiting | 166 |
| 2027-01-29 est. | P2 | Dynavax Technologies Corporation | NCT07207408 Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | active not recruiting | 148 |
| 2027-01-30 est. | P3 | Tolmar Inc. | NCT04906395 Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | Breast Cancer | active not recruiting | 250 |
| 2027-01-30 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06132217 A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | Advanced Solid Tumor | not yet recruiting | 168 |
| 2027-01-30 est. | P2 | Curasight | NCT06474806 Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer | Prostate Cancer | recruiting | 168 |
| 2027-01-30 est. | P1/P2 | Psivac Ltd | NCT06549946 Ixovex-1 Single Agent and Combination Therapy | Solid Tumor; Head and Neck Cancer | recruiting | 18 |
| 2027-01-30 est. | P3 | Hoffmann-La Roche | NCT06589986 A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Sever | Moderately to Severely Active Ulcerative Colitis | active not recruiting | 400 |
| 2027-01-30 est. | P3 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06656091 A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | Advanced Oesophageal Squamous Cell Carcinoma | not yet recruiting | 450 |
| 2027-01-30 est. | P3 | Sinovac Biotech Co., Ltd SVA | NCT07055893 Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen | Rabies (Healthy Volunteers) | not yet recruiting | 390 |
| 2027-01-31 est. | P2 | Scancell Ltd SCNLD | NCT04079166 SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | Malignant Melanoma; Melanoma (Skin); Melanoma Stage III; Melanoma Stage IV | active not recruiting | 173 |
| 2027-01-31 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99 | Urinary Bladder Neoplasms | active not recruiting | 520 |
| 2027-01-31 est. | P2 | Daiichi Sankyo Co., Ltd. | NCT04433234 Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | active not recruiting | 8 |
| 2027-01-31 est. | P3 | Actelion | NCT05179876 A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | Hypertension, Pulmonary | recruiting | 280 |
| 2027-01-31 est. | P1/P2 | Creative Medical Technology Holdings Inc CELZ | NCT05626712 Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Type 1 Diabetes; Diabetes Mellitus, Type 1 | recruiting | 18 |
| 2027-01-31 est. | P3 | iRenix Medical, Inc. | NCT05750589 Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections | Retinal Disease | not yet recruiting | 240 |
| 2027-01-31 est. | P1/P2 | Janssen Research & Development, LLC | NCT05908734 A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | active not recruiting | 71 |
| 2027-01-31 est. | P2 | Grit Biotechnology | NCT06241781 Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2027-01-31 est. | P1/P2 | EXO Biologics S.A. | NCT06279741 Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants | Bronchopulmonary Dysplasia | recruiting | 265 |
| 2027-01-31 est. | P3 | Ono Pharmaceutical Co., Ltd. | NCT06579573 ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. | Epilepsy, Generalized | recruiting | 15 |
| 2027-01-31 est. | P2 | Ono Pharmaceutical Co., Ltd. | NCT06590896 Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures | Epilepsies, Partial | recruiting | 100 |
| 2027-01-31 est. | P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06739213 A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma | Recurrent or Progressive High Grade Meningioma | not yet recruiting | 56 |
| 2027-01-31 est. | P2 | NeuroBiogen Co., Ltd | NCT07009171 Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients | Overweight; Obesity; Obese Patients | recruiting | 75 |
| 2027-01-31 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT07202364 A Study of YL202 in Patients With Advanced Solid Tumors | Non Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solid | recruiting | 100 |
| 2027-01-31 est. | P2 | Miltenyi Biomedicine GmbH | NCT07288879 DALY II Japan/MB-CART2019.1 for DLBCL | DLBCL - Diffuse Large B Cell Lymphoma; CAR T Cell Therapy | recruiting | 31 |
| 2027-01-31 est. | P2 | Dermavon Holdings Limited | NCT07465120 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moder | Moderate to Severe Atopic Dermatitis | not yet recruiting | 160 |
| 2027-01-31 est. | P2/P3 | Quoin Pharmaceuticals QNRX | NCT07538583 Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | recruiting | 16 |
| 2027-01-31 est. | P2 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT07940075 SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension . | Mild to Moderate Primary Hypertension | recruiting | 360 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.